Download PDF
Thromb Haemost 1986; 56(03): 241-242
DOI: 10.1055/s-0038-1661657
Editorial
Schattauer GmbH Stuttgart

Current Status of Low Molecular Weight Heparin

Duncan P Thomas
National Institute for Biological Standards and Control, London NW3 6RB, UK
› Author Affiliations
Further Information

Publication History

Received 10 July 1986

Accepted 26 August 1986

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Prevention of deep venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-749
    CrossrefPubMedGoogle Scholar
  • 2 Kakkar VV. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet 1975; 2: 45-51
    PubMedGoogle Scholar
  • 3 Johnson EA, Kirkwood TB L, Stirling Y, Perez-Requejo JL, Ingram GI C, Bangham DR, Brozovic M. Four heparin preparations: antiXa potentiating effect of heparin after subcutaneous injection. Thromb Haemostas 1976; 35: 586-591
    PubMedGoogle Scholar
  • 4 Barrowcliffe TW B, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 575-583
    PubMedGoogle Scholar
  • 5 Anderson L-O, Barrowcliffe TW B, Holmer E, Johnson EA, Simms G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
    CrossrefPubMedGoogle Scholar
  • 6 Thomas DP. Heparin in the prophylaxis and treatment of venous thromboembolism. Sem Haematol 1978; 15: 1-7
    PubMedGoogle Scholar
  • 7 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
    CrossrefPubMedGoogle Scholar
  • 8 Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-353
    CrossrefPubMedGoogle Scholar
  • 9 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
    CrossrefPubMedGoogle Scholar
  • 10 Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemostas 1986; 56: 243-246
    PubMedGoogle Scholar
  • 11 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-248
    PubMedGoogle Scholar
  • 12 Holmer E, Mattson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 13 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
    CrossrefPubMedGoogle Scholar
  • 14 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
    PubMedGoogle Scholar
  • 15 Esquivel CO, Bergqvist D, Bjorck C-G, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-399
    CrossrefPubMedGoogle Scholar
  • 16 Bjorck C-G, Bergqvist D, Esquivel C, Nilsson B, Rudsvik Y. Effect of heparin, low molecular weight (LMWH) heparin and an analogue on experimental venous thrombosis in the rabbit. Acta Chir Scand 1984; 150: 629
    PubMedGoogle Scholar
  • 17 Pangrazzi J, Abbadini M, Zametta M, Naggi A, Torri G, Casu B, Donati MB. Antithrombotic and bleeding effects of a low molecular weight heparin fraction. Biochem Pharmacol 1985; 34: 3305-3308
    CrossrefPubMedGoogle Scholar
  • 18 Bratt G, Tornebohm E, Lockner D, Bergstrom K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemostas 1985; 53: 208-211
    PubMedGoogle Scholar
  • 19 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
    PubMedGoogle Scholar
  • 20 Kakkar VV, Djazaeri B, Fox J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of post-operative deep vein thrombosis. Br Med J 1982; 284: 375-379
    CrossrefPubMedGoogle Scholar
  • 21 Kakkar VV, Murray WJ G. Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar
  • 22 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedGoogle Scholar
  • 23 Salzman EW. Low molecular weight heparin - is small beautiful?. N Engl J Med 1986; 315: 957-959
    CrossrefPubMedGoogle Scholar